FBXL2: F-Box and Leucine Rich Repeat Protein 2
A substrate recognition component of the SCF ubiquitin ligase complex involved in cell cycle regulation and tumor suppression.
Gene Information Card
| Symbol | FBXL2 |
|---|---|
| Full Name | F-Box and Leucine Rich Repeat Protein 2 |
| Gene Type | Protein coding |
| Chromosomal Location | 3p22.3 |
| NCBI Gene ID | 25827 ncbi.nlm.nih.gov/gene/25827 |
| Ensembl ID | ENSG00000163882 |
| UniProt ID | Q9UKC9 |
| OMIM ID | 609047 |
| HGNC ID | 13601 |
| Aliases | FBL2, FBL2_HUMAN, F-box/LRR-repeat protein 2 |
Description
FBXL2 encodes a member of the F-box protein family, characterized by an F-box domain and leucine-rich repeats (LRRs). As a substrate recognition component of the SCF (SKP1-CUL1-F-box protein) E3 ubiquitin ligase complex, FBXL2 targets specific proteins for ubiquitination and proteasomal degradation. It plays a critical role in cell cycle progression, apoptosis, and tumor suppression by regulating the stability of key proteins such as cyclin D2, cyclin D3, and CDK6. FBXL2 is located on chromosome 3p22.3, a region frequently deleted in various cancers.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Lung cancer | FBXL2 downregulation leads to increased cyclin D2 and CDK6 stability, promoting cell proliferation. | PMID: 23541922, COSMIC |
| Colorectal cancer | Loss of FBXL2 expression correlates with poor prognosis and enhanced tumor growth. | PMID: 26056037 |
| Breast cancer | FBXL2-mediated degradation of cyclin D3 is impaired, contributing to oncogenesis. | PMID: 27134142 |
| Hepatocellular carcinoma | FBXL2 acts as a tumor suppressor; reduced expression linked to aggressive disease. | PMID: 28891466 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Testis | 12.5 | Medium |
| Lung | 8.3 | Medium |
| Brain | 6.1 | Low |
| Liver | 5.4 | Low |
| Heart | 4.2 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HeLa | 9.8 | Cervical cancer cell line |
| A549 | 7.5 | Lung adenocarcinoma cell line |
| HCT116 | 6.3 | Colorectal carcinoma cell line |
| MCF7 | 5.1 | Breast cancer cell line |
| HEK293 | 4.7 | Embryonic kidney cell line |
Data source:Human Protein Atlas(proteinatlas.org)
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1015C>T (p.Arg339*) | Nonsense | <0.1% | Loss of function; truncation of LRR domain |
| c.1246G>A (p.Gly416Arg) | Missense | <0.1% | Unknown; predicted damaging by SIFT |
| c.178_179insA (p.Thr60Asnfs*12) | Frameshift | <0.1% | Loss of function; premature stop codon |
Mutation functional classification
Loss of Function (LOF)
Nonsense and frameshift mutations (e.g., p.Arg339*, p.Thr60Asnfs*12) result in truncated or absent protein, impairing substrate ubiquitination and leading to oncogenic stabilization of cyclins and CDKs.
Gain of Function (GOF)
No gain-of-function mutations reported in FBXL2.
Dominant Negative (DN)
No dominant-negative mutations reported in FBXL2.
View complete mutation data:
Gene Ontology (GO)
Pathways
• Ubiquitin mediated proteolysis (KEGG: hsa04120)
• Cell cycle (KEGG: hsa04110)
• SCF complex assembly (Reactome: R-HSA-8951664)
Protein Summary
FBXL2 is a 433-amino acid protein containing an N-terminal F-box domain (residues 33-78) and C-terminal leucine-rich repeats (LRRs, residues 120-420). The F-box domain mediates interaction with SKP1, while LRRs are responsible for substrate recognition. FBXL2 targets cyclin D2, cyclin D3, and CDK6 for ubiquitination and degradation, thereby negatively regulating cell cycle progression. Loss of FBXL2 expression or function contributes to tumorigenesis in multiple cancer types.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| FBXL2 Knockout HEK293 Cell Line | EDJ-KQ2843 | Human | 25827 | Details Get a Quote |
| FBXL20 Knockout HEK293 Cell Line | EDJ-KQ10285 | Human | 84961 | Details Get a Quote |
| FBXL22 Knockout HEK293 Cell Line | EDJ-KQ13459 | Human | 283807 | Details Get a Quote |
| FBXL2 Knockout A-549 Cell Line | EDJ-KQ23840 | Human | 25827 | Details Get a Quote |
| FBXL2 Knockout HCT 116 Cell Line | EDJ-KQ23841 | Human | 25827 | Details Get a Quote |
| FBXL2 Knockout HeLa Cell Line | EDJ-KQ23842 | Human | 25827 | Details Get a Quote |
| FBXL20 Knockout A-549 Cell Line | EDJ-KQ36293 | Human | 84961 | Details Get a Quote |
| FBXL20 Knockout HCT 116 Cell Line | EDJ-KQ37545 | Human | 84961 | Details Get a Quote |
| FBXL20 Knockout HeLa Cell Line | EDJ-KQ37546 | Human | 84961 | Details Get a Quote |
| FBXL22 Knockout HeLa Cell Line | EDJ-KQ59413 | Human | 283807 | Details Get a Quote |
| FBXL22 Knockout A-549 Cell Line | EDJ-KQ67881 | Human | 283807 | Details Get a Quote |
| FBXL22 Knockout HCT 116 Cell Line | EDJ-KQ76261 | Human | 283807 | Details Get a Quote |